secwatch.observer — SEC 8-K summary
======================================

Issuer:     Unicycive Therapeutics, Inc. (UNCY)
CIK:        0001766140
Form:       8-K
Filed at:   2024-03-14T23:59:59+00:00
Accession:  0001213900-24-022600
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 1.01, 3.02, 5.03, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Unicycive exchanges 43.6M Series A-2 preferred shares for 21,388 new preferred, amends warrants
--------------------------------------------------------------------------------

- Exchanged 43,649,000 Series A-2 Preferred shares for 21,388.01 shares of new Series A-2 Prime Preferred.
- Amended Tranche A, B, C warrants; reduced shares issuable, set exercise price at $1,000 per share.
- New preferred series have conversion prices from $0.49 to $0.74 per share of common stock.
- All prior Series A-1 through A-5 preferred eliminated via Certificates of Elimination.
- Exchange treated as tax-free recapitalization under Sections 368(a)(1)(e) and/or 1036 of the Code.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1766140/000121390024022600/0001213900-24-022600-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1766140/000121390024022600/ea0201786-8k_unicyc.htm
  HTML page:      https://secwatch.observer/filing/0001213900-24-022600

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer